Zynerba Press Releases

20 Feb 20 Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual Meeting

3 Feb 20 Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome

13 Jan 20 Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome

13 Jan 20 Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

12 Nov 19 Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol

5 Nov 19 Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

25 Oct 19 Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

26 Sep 19 Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

18 Sep 19 Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)

5 Sep 19 Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms